ARVO 2023: Insights at the annual meeting regarding non-viral gene therapy targeting ABCA4 retinopathies
Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.
Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Theresa Heath, MD, MBA:
I'm really pleased to be here today to give you an update of what we're doing at Intergalactic Therapeutics. We are transforming medicine in nonviral gene therapy and just released our 12-month persistent expression data [inaudible] for lead program called ABCA4-associated retinopathies, or IG-002.
So, the meeting went well. The presentation was really great, we were able to show persistent expression, durability, and more importantly, safety. So, we're really excited to enter IND next year and to start clinical trials next year. I think it's fantastic. With this nonviral gene therapy approach, it can really overcome safety, but more importantly, effectiveness and efficiency for delivering this large payload capacity of the gene to all patients.
What we're also doing is delivering this with a CMC manufacturing process, that allows patient accessibility due to the scalability and the low costs of goods.
